<DOC>
	<DOC>NCT00137020</DOC>
	<brief_summary>The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) scores versus baseline</brief_summary>
	<brief_title>Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Primary diagnosis of schizophrenia or schizoaffective disorder, using DSMIV criteria. Currently receiving either haloperidol, olanzapine or risperidone within /+ 25% of the recommended daily dose (as delineated by the medication's package insert Resistance to conventional antipsychotic drugs With antipsychotic agents other than olanzapine, risperidone or haloperidol at start of treatment regimen within 12 hours prior to first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2006</verification_date>
</DOC>